Business Context and Reporting Period
Company: Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP)
Filing Type: Form 8-K (Current Report)
Report Date: June 14, 2024 (Events reported through June 20, 2024)
Context: The filing reports a private placement of Series A Preferred Stock, the grant of CEO stock options, and the issuance of a press release regarding the financing closing.
Key Financial Metrics and Capital Structure
Capital Raised: $4.3 million in gross proceeds.
Instrument: 4,300 shares of Series A Preferred Stock sold at $1,000 per share.
Payment Method: Combination of cash and short-term collateralized promissory notes.
Additional Equity Interest: Investors received a 6.45% non-voting equity ownership interest in two newly formed subsidiaries: SNAP Biosciences Inc. and GEAR Therapeutics Inc.
CEO Compensation Grant: 2,400,000 fully vested stock options granted to CEO David Mehalick with a 10-year term.
Financial Statements: The filing text does not provide specific values for revenue, profit, cash flow, margins, or total debt.
Material Changes and Transaction Terms
- Series A Preferred Stock Terms:
- Conversion: Initial conversion price of $0.40 per share of common stock. Automatic conversion triggers upon a fundraising transaction raising at least $20 million in gross proceeds.
- Rank: Senior to common stock and other classes not senior or pari passu.
- Dividends: Paid on an "as-if-converted" basis when common stock dividends are paid.
- Liquidation Preference: Holders receive the greater of the Stated Value ($1,000) plus accrued dividends or the amount payable if converted immediately prior to liquidation.
- Voting: Voted on an "as converted" basis.
- Limitations: Conversion and dividend rights are subject to beneficial ownership limitations (20% threshold) and Nasdaq market limitations (19.99% of outstanding common stock).
Guidance, Outlook, and Risks
Outlook: The filing does not contain specific financial guidance or forward-looking projections regarding revenue or clinical milestones.
Risks and Contingencies:
- Conversion Restrictions: The ability of investors to convert preferred stock into common stock is restricted by beneficial ownership caps and Nasdaq listing rules regarding share issuance limits.
- Automatic Conversion Trigger: The preferred stock will automatically convert if the company raises $20 million or more in a future fundraising transaction.
Investor Verification Checklist
- Verify the exact split of proceeds between cash and short-term collateralized promissory notes.
- Confirm the current outstanding share count of common stock to assess the potential dilution impact of the Series A Preferred Stock conversion at $0.40 per share.
- Review the terms of the short-term collateralized promissory notes for interest rates and maturity dates.
- Assess the impact of the 2,400,000 CEO stock options on future dilution and cash flow if exercised.
- Examine the financial health and strategic role of the newly formed subsidiaries (SNAP Biosciences Inc. and GEAR Therapeutics Inc.) regarding the 6.45% investor stake.